Oventus is pleased to announce it has launched a fully underwritten Initial Public Offer to raise $12 million.
Oventus is offering 24 million shares to be listed on the Australian Securities Exchange at $0.50 a share.
Oventus recently received clearance from the US Food and Drug Administration to market the O2VENTTM device, providing further validation for its technology and a step to expanding into international markets.
Our mission is to be a global leader in the treatment of obstructive sleep apnoea (OSA) with an initial focus on those who cannot, or are not, treated effectively with existing treatments. OSA (repeated episodes of airway obstruction during sleep) is commonly associated with snoring but also has a direct link to more serious health issues.
Funds raised under the Offer will be used to continue the commercialisation and distribution of this device in Australia, develop additional devices, as well as commence expansion into other jurisdictions.
We are pleased to invite investors to join with Oventus as we embark on an exciting development program and help address a significant health and lifestyle issue for millions of people around the world.
A copy of the Prospectus is now available on the Company’s website www.oventusmedicalinvestors.com or from Bell Potter Securities.